| abstract |
The present disclosure relates to group II intron splicing factors, nucleic acids encoding group II intron splicing factors, and methods of using the nucleic acids and proteins encoded thereby. In particular, the present disclosure relates to methods of inhibiting the in vivo functions of the disclosed group II intron splicing factors. |